Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
作者信息
Mastorino Luca, Roccuzzo Gabriele, Dapavo Paolo, Siliquini Niccolò, Avallone Gianluca, Rubatto Marco, Quaglino Pietro, Ribero Simone
机构信息
Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
出版信息
Dermatol Ther. 2022 Sep;35(9):e15697. doi: 10.1111/dth.15697. Epub 2022 Jul 19.
Abstract
摘要
相似文献
1
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?从白细胞介素23抑制剂转换为白细胞介素17抑制剂：一种安全有效的做法？
Dermatol Ther. 2022 Sep;35(9):e15697. doi: 10.1111/dth.15697. Epub 2022 Jul 19.
2
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease.白细胞介素23在溃疡性结肠炎和克罗恩病中对Th1/Th17平衡有不同的调节作用。
Gut. 2008 Dec;57(12):1682-9. doi: 10.1136/gut.2007.135053. Epub 2008 Jul 24.
3
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies.IL17/23 轴在银屑病中的主要作用支持新靶向治疗的发展。
Front Immunol. 2021 Feb 25;12:621956. doi: 10.3389/fimmu.2021.621956. eCollection 2021.
4
Psoriasis and the TNF/IL23/IL17 axis.银屑病与 TNF/IL23/IL17 轴。
G Ital Dermatol Venereol. 2019 Aug;154(4):418-424. doi: 10.23736/S0392-0488.18.06202-8. Epub 2019 Jan 15.
5
Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study.关于《银屑病治疗中IL-12/23、IL-17和IL-23抑制剂的药物生存情况：一项回顾性多国多中心队列研究》的评论
Am J Clin Dermatol. 2021 Nov;22(6):901-902. doi: 10.1007/s40257-021-00642-3. Epub 2021 Oct 27.
6
Gene expression of IL17 and IL23 in the lungs of patients with active tuberculosis.活动性肺结核患者肺部白细胞介素17和白细胞介素23的基因表达
Thorax. 2008 Jun;63(6):566-8. doi: 10.1136/thx.2007.092205.
7
Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus.血浆白细胞介素22水平降低，而非白细胞介素17和白细胞介素23水平升高，与系统性红斑狼疮患者的疾病活动相关。
Ann Rheum Dis. 2009 Apr;68(4):604-6. doi: 10.1136/ard.2008.097089.
8
Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.抑制白细胞介素-17、白细胞介素-23及TH17细胞通路在银屑病关节炎和银屑病治疗中的应用
Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.0000000000000147.
9
IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3.产生白细胞介素23的人肺癌细胞通过将先天性淋巴细胞1（ILC1）转化为ILC3促进肿瘤生长。
Clin Cancer Res. 2019 Jul 1;25(13):4026-4037. doi: 10.1158/1078-0432.CCR-18-3458. Epub 2019 Apr 12.
10
Possible association of proinflammatory cytokines including IL1β and TNFα with enhanced Th17 cell differentiation in patients with Behcet's disease.白塞病患者中包括IL1β和TNFα在内的促炎细胞因子与Th17细胞分化增强之间可能存在关联。
Clin Rheumatol. 2016 Jul;35(7):1857-63. doi: 10.1007/s10067-015-2966-2. Epub 2015 May 14.
引用本文的文献
1
Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland.波兰中度至重度银屑病患者队列中白细胞介素-17抑制剂长期真实世界疗效的比较分析
J Clin Med. 2025 Aug 1;14(15):5421. doi: 10.3390/jcm14155421.
2
Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis.在葡萄牙中度至重度银屑病患者队列中使用布罗达单抗的真实世界经验。
Drugs Context. 2025 Mar 14;14. doi: 10.7573/dic.2024-11-4. eCollection 2025.
3
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.司库奇尤单抗治疗银屑病：关于早期治疗及真实世界证据的叙述性综述
Dermatol Ther (Heidelb). 2024 Oct;14(10):2739-2757. doi: 10.1007/s13555-024-01255-4. Epub 2024 Sep 24.
4
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.一项为期六个月的真实世界研究，旨在评估从白细胞介素-23抑制剂和其他生物疗法转换为司库奇尤单抗后的有效性：CorEvitas银屑病注册研究。
Drugs Real World Outcomes. 2024 Sep;11(3):451-464. doi: 10.1007/s40801-024-00439-w. Epub 2024 Jun 24.
5
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.银屑病中IL17和IL23抑制剂之间的跨类转换：一项真实生活、长期、单中心经验
J Clin Med. 2023 Dec 5;12(24):7503. doi: 10.3390/jcm12247503.
6
Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study.银屑病患者对不同类型生物治疗反应的衰老影响：一项真实世界观察性研究。
J Clin Med. 2023 Nov 21;12(23):7215. doi: 10.3390/jcm12237215.
7
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study.白细胞介素-17与白细胞介素-23抑制剂治疗脓疱型和红皮病型银屑病的回顾性多中心队列研究
J Clin Med. 2023 Feb 19;12(4):1662. doi: 10.3390/jcm12041662.
本文引用的文献
1
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population.对多种生物疗法耐药的银屑病患者：难治性人群的特征与定义
Br J Dermatol. 2022 Aug;187(2):263-265. doi: 10.1111/bjd.21048. Epub 2022 May 24.
2
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study.IL-23、IL-17 和 TNF-α 抑制剂治疗银屑病的疗效、安全性和药物生存情况：一项回顾性研究。
J Dermatolog Treat. 2022 Jun;33(4):2352-2357. doi: 10.1080/09546634.2021.1961998. Epub 2021 Aug 13.
3
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，ixekizumab与guselkumab的头对头比较：一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
4
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.从司库奇尤单抗转换为乌司奴单抗治疗银屑病患者：一项多中心经验的结果。
Dermatology. 2019;235(3):213-218. doi: 10.1159/000497274. Epub 2019 Mar 29.
5
When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.当白细胞介素 17 抑制剂失效时：从司库奇尤单抗转换为阿达木单抗或乌司奴单抗的真实世界证据。
Dermatol Ther. 2019 Mar;32(2):e12793. doi: 10.1111/dth.12793. Epub 2018 Dec 21.
6
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.
7
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.替西单抗与安慰剂或依那西普治疗慢性斑块型银屑病（reSURFACE 1 和 reSURFACE 2）：两项随机对照、3 期临床试验的结果。
Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6.
8
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
Zotero 插件